Purpose: In some patients with Hodgkin lymphoma (HL), proton beam therapy (PBT) may reduce the risk of radiation-related cardiovascular disease (CVD) and second cancers (SC) compared with photon radiation therapy (RT). Our aim was to identify patients who benefit the most from PBT in terms of predicted 30-year absolute mortality risks (AMR30) from CVD and SC, taking into account individual background, chemotherapy, radiation, and smoking-related risks.

Methods and Materials: Eighty patients with supradiaphragmatic HL treated with PBT between 2015 and 2019 were replanned using optimal photon RT. To identify patients predicted to derive the greatest benefit from PBT compared with photon RT, doses and AMR30 from CVD and SC of the lung, breast, and esophagus were compared for all patients and across patient subgroups.

Results: For patients with mediastinal disease below the origin of the left main coronary artery (n = 66; 82%), PBT reduced the mean dose to the heart, left ventricle, and heart valves by 1.0, 2.7, and 3.6 Gy, respectively. Based on U.S. mortality rates, PBT reduced CVD AMR30 by 0.2%, from 5.9% to 5.7%. The benefit was larger if the mediastinal disease overlapped longitudinally with the heart by ≥40% (n = 23; 29%). PBT reduced the mean dose to the heart, left ventricle, and heart valves by 3.2, 5.6, and 5.1 Gy, respectively, and reduced CVD AMR30 by 0.8%, from 7.0% to 6.2%. For patients with axillary disease (n = 25; 31%), PBT reduced the mean lung dose by 2.8 Gy and lung cancer AMR30 by 0.6%, from 2.7% to 2.1%. Breast and esophageal doses were also lower with PBT, but the effects on AMR30 were negligible. The effect of smoking on CVD and lung cancer AMR30 was much larger than radiation and chemotherapy and the differences between radiation modalities.

Corresponding author: Georgios Ntentas, DPhil; E-mail: georgios.ntentas@ndph.ox.ac.uk

N. George Michaeel and David J. Cutter made equal contributions to this study.

Disclosures: G.N. was supported by a DPhil studentship and Early Career Postdoctoral Research Fellowship from the University of Oxford. S. C.D., M.A., J.R., and D.I.C. were supported by Cancer Research UK (grant no C8225/A21133) and the University of Oxford. These funding bodies had no role in the collection, analysis or interpretation of the data, or writing of the report. R.S. is supported by a National Institute of Health Research Doctoral Fellowship (NIHR300740). This report is independent research supported by the National Institute of Health Research. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, National Institute for Health Research, or Department of Health and Social Care. No conflicts of interest to disclose.

Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ijrobp.2021.10.151.
Conclusions: The predicted benefit of PBT is not universal and limited to certain categories of patients with lymphoma and lower mediastinal or axillary disease. Smoking cessation should be strongly encouraged in smokers who require thoracic RT. © 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Introduction

Patients with Hodgkin lymphoma (HL) are at risk of treatment-related long-term effects, including cardiovascular disease (CVD) and second cancers (SC) of the lung, breast, and esophagus. Most estimates of the magnitude of these risks are based on patients treated many decades ago using outdated radiation therapy (RT) techniques (eg, mantle RT, which delivered high radiation doses to target volumes and organs at risk [OARs]). In recent decades, reductions in treatment volumes and prescription doses, as well as advances in medical imaging and photon RT technology, have maintained lymphoma treatment efficacy while reducing incidental radiation doses to OARs substantially. As a result, some studies have reported that patients treated in the last few decades have lower risks than those treated many decades ago. However, even for those treated today, the risks of CVD and SC in some patients with HL may remain higher than those of the general population.

The introduction of proton beam therapy (PBT), which can deliver radiation doses more conformally than conventional RT, has offered the potential to further reduce radiation doses to OARs when treating patients with HL. However, PBT is more complex and expensive than conventional RT and less widely available, raising the need for appropriate patient selection. Recent guidelines by the International Lymphoma Radiation Oncology Group (ILROG) identify subgroups of patients with HL who may benefit substantially from PBT compared with photon RT. These subgroups include patients whose mediastinal disease extends below the origin of the left main stem coronary artery (LMSCA), young women, and patients with relapsed disease.

Reducing radiation doses to OARs is expected to be beneficial, but the link between dose reduction and the absolute magnitude of clinical benefit is not always clear. Late effects depend on other factors, as well as radiation dose, including age, sex, chemotherapy use, smoking status, and the disease rates of the general population in the patient’s geographic region. Therefore, considering radiation dose reduction alone does not give a full picture of the expected clinical benefit of PBT. The purpose of this study is to compare PBT with the current best photon RT technique to identify which patients benefit the most from PBT, not only in terms of radiation dose reductions to specific OARs, but by predicting the more clinically meaningful endpoint of 30-year absolute mortality risk (AMR30) for CVD and SC in a large group of patients with HL who were treated with PBT. In addition to radiation-related risk, we also examined the role of other risk factors in determining AMR30, namely chemotherapy, smoking status, and mortality rates in the general population. To our knowledge, this is the first study to evaluate the selection of patients with lymphoma for PBT using AMR30 and clinical data from patients actually treated with PBT.

Methods and Materials

Patients and treatment planning

Between April 2015 and April 2019, a total of 80 consecutive patients with HL and mediastinal disease (50 women and 30 men) were treated with anthracycline-containing chemotherapy, followed by pencil beam scanning PBT in deep inspiration breath hold (DIBH) at the Proton Therapy Center Czech s.r.o. The prescribed doses in Gy equivalent (GyE; relative biologic effectiveness of 1.1) were 30 GyE in 15 fractions (75 patients), 20 GyE in 10 fractions (3 patients), 36 GyE in 18 fractions (1 patient), and 40 GyE in 20 fractions (1 patient). Radiation target volumes were defined as involved sites for all early and intermediate-stage patients and residual disease for advanced-stage patients.

The ILROG recommendations for gross tumor volume and clinical target volume (CTV) definitions were used. The heart and cardiac substructures were contoured according to published atlases. The PBT planning methodologies have been described in a previous study. Alternative photon RT plans were produced using the same DIBH scans. CTV to planning target volume (PTV) margins that reflect current clinical practice were used (ie, 5 mm for photon RT plans and 7-12 mm for PBT plans). For both proton and photon therapy, OAR dose objectives were set individually to achieve the lowest possible doses considering the individual anatomy and clinical characteristics for the patient.

All plans were produced by experienced physicists, and reviewed and approved by senior radiation oncologists from 2 different institutions (University of Oxford and Guy’s and St Thomas’ NHS Foundation Trust). The photon RT planning method used for most patients with mediastinal and neck disease was butterfly volumetric arc therapy (BVMAT), but for more complex volumes (eg, those involving the axilla or extended volumes), additional plans were produced using BVMAT with additional partial arcs (PartArc) or full-arc BVMAT (FaB-VMAT) and then compared. In total, 3 planning methods were used: BVMAT (45 patients), PartArc (30 patients), and FaB-VMAT (5 patients) depending on the photon RT deemed the best plan based on PTV coverage and OAR doses. All plans were
produced on Eclipse, version 15.0. The study was approved by the institutional review board of the Proton Therapy Center Czech s.r.o.

Comparison of radiation doses

For each individual, the difference between photon RT and PBT was calculated for the radiation dose to the OAR (whole heart, 12 cardiac substructures, lungs, breast, esophagus, larynx, spinal cord, and thyroid), RT PTV, and normal tissue dose (whole body minus PTV). To identify patients who would derive the greatest benefit from PBT in dosimetric terms, cardiac dose differences were compared separately for patients whose mediastinal disease extended above or below the origin of the LMSCA, as suggested in the ILROG guidelines, and for patients whose disease extended above or below the 7th thoracic vertebra (T7).

Additionally, the percentage longitudinal overlap between the extent of the disease (specified by CTV extent) and the heart (Appendix A-Fig. E1) was examined as a potential indicator of benefit from PBT for heart doses. Lung and breast doses were also studied for patients with and without axillary disease. The differences in doses between these subgroups and by sex were examined using a linear regression model. Significance tests were 2-sided and conducted using the \( t \) distribution. Calculations were performed in Stata, version 14.2 (Stata Corp LLC).

Cardiovascular and second cancer risk prediction

The AMR\(_{30}\) for CVD and for each of the SC was predicted for the patients in this study, taking into account the competing risk of death from other causes, and calculated in 3 steps. First, for each of the 80 patients, the background cumulative mortality risk (in the absence of any lymphoma-or treatment-related risk) was predicted using mortality rates in the general population. To do this, attained-age and sex-specific mortality rates corresponding to each patient were obtained from the World Health Organization mortality database. Then, these risks were averaged across all 80 patients for each of the 30 years after treatment. Second, the calculations were repeated taking into account the chemotherapy-related increase in the mortality rate for CVD. Finally, the calculations were repeated again taking into account the RT-related increases in CVD and SC mortality rates, as well as the chemotherapy-related increase in CVD.

The above treatment-related increases in the mortality rates for CVD and SC were derived from published dose—response relationships, including age at treatment-specific values where appropriate combined with patient-specific mean radiation doses to relevant organs or cardiac substructures (Table E5). For CVD, the mortality rate, including the effect of treatment, was the sum of the mortality rates for coronary heart disease, congestive heart failure, valvular heart disease, other cardiac diseases, and stroke. Dose—response relationships were not available for other cardiac diseases (eg, pericardial disease and arrhythmias), and the approach used for this group is described in Appendix B.

Risks were predicted for all patients combined, as well as for the patient subgroups in the dosimetric analysis. Separate calculations were performed using background mortality rates in the 4 different geographic regions in which PBT is currently available (United States, Western Europe, Eastern Europe, and Japan). Finally, U.S. mortality rates were used to investigate the effect of smoking on the cumulative mortality risks for CVD and lung cancer for 30-year-old male and female current smokers and never-smokers by assuming the average mean heart dose (MHD), mean left ventricular dose (MLVD), and heart valve dose (SumValve) delivered by PBT and photon RT in patients with \( \geq 40\% \) CTV-to-heart overlap for CVD. For lung cancer, the average mean lung dose (MLD) received by patients with axillary disease was used. The risk prediction methodology is detailed in Appendices B and C.

Results

Characteristics of patients with HL

The median age at the time of treatment was 30 years (range, 18-79 years), and 50 patients (62%) were female (Table 1). Sixty-seven patients (84%) had early favorable or intermediate (IIA/B) stage disease. All patients completed PBT without interruptions. With a median follow-up time of 24 months (range, 3-56 months), all but 2 patients (97.5%) achieved complete remission. No severe (grade 3-4) toxicities or radiation pneumonitis of any grade were reported. Grade 2 toxicities were reported for a few patients (Table E4).

Comparison of radiation doses from PBT and photon-RT

For all 80 patients, PTV coverage was \( >95\% \) of the prescribed dose for both PBT and photon RT plans. When all patients were considered together, PBT reduced the average MHD compared with photon RT but not significantly (\( -0.7 \) Gy; \( P = .06 \)). However, PBT delivered significantly lower average MLVD (\( -2.2 \) Gy; \( P < .001 \)) and SumValve (\( -2.7 \) Gy; \( P < .001 \); Table 2). For the 82% of patients whose CTV extended below the LMSCA and the 59% of patients whose CTV extended below the T7 level, there were significant reductions in cardiac doses with PBT. For patients whose CTV did not extend below the LMSCA or T7, PBT did not confer any significant dose reductions and, in some cases, increased cardiac doses compared with photon RT (Table 2; Supplemental Table E5). The largest dose reductions for PBT compared with photon RT were observed for the approximately 30% of patients whose CTV overlapped longitudinally with the heart by \( \geq 40\% \) (MHD: \( -3.2 \) Gy; MLVD: \( -5.6 \) Gy; and SumValve: \( -5.1 \) Gy; all \( P < .001 \);
Table 2). For patients with a <40% overlap, there was no dosimetric benefit with PBT for MHD (+0.4 Gy; P = .29), although both MLVD and SumValve were somewhat reduced with PBT, by −0.9 Gy (P = .04) and −1.7 Gy (P = .02), respectively.

Compared with photon RT, PBT delivered higher doses to the carotid arteries (average increase for all patients: +2.0 Gy; P < .001) but lower doses to the lungs (−2.2 Gy; P < .001), female breast (−0.9 Gy; P < .001), and esophagus (−1.2 Gy; P = .003). The reductions in lung and breast doses were greater for patients whose axilla was irradiated (lungs: −2.8 Gy; P < .001; breast: −1.8 Gy; P < .001; Table 2).

Table 1 Characteristics of 80 patients with supradiaphragmatic Hodgkin lymphoma treated with proton beam therapy

| Number of patients (%) | Median dose of anthracyclines 340 mg/m² (range, 170–420 mg/m²²) |
|------------------------|---------------------------------------------------------------|
|                         | 6 × escalated BEACOPP                                         |
|                         | 2 × escalated BEACOPP + 2 × ABVD                              |
|                         | 4 × ABVD                                                      |
|                         | Other                                                         |
|                         |                                                              |
| Age at time of RT       |                                                              |
| Median age: 30.5 y (range, 18-79 y) | -- |
| Smoking status at time of HL diagnosis | -- |
| Never smoker            | 39 (49)                                                      |
| Current/former smoker   | 25 (31)                                                      |
| Unknown                 | 16 (20)                                                      |
| Follow up after RT      |                                                              |
| Median follow up: 24 mo (range, 3-56 mo) | -- |

Table 1 (Continued)

| Number of patients (%) | Median dose of anthracyclines 340 mg/m² (range, 170–420 mg/m²²) |
|------------------------|---------------------------------------------------------------|
|                         | 6 × escalated BEACOPP                                         |
|                         | 2 × escalated BEACOPP + 2 × ABVD                              |
|                         | 4 × ABVD                                                      |
|                         | Other                                                         |
| Patient subgroups      |                                                              |
| Longitudinal overlap CTV/heart | -- |
| ≤40% overlap           | 57 (71)                                                      |
| ≥40% overlap           | 23 (29)                                                      |
| CTV inferior extension vs left main stem coronary artery | -- |
| At and above only      | 14 (18)                                                      |
| Below                  | 66 (82)                                                      |
| CTV inferior extension vs vertebral thoracic level | -- |
| At and above seventh thoracic level | 33 (41) |
| Below seventh thoracic level | 47 (59) |

Table 2). For patients with a <40% overlap, there was no dosimetric benefit with PBT for MHD (+0.4 Gy; P = .29), although both MLVD and SumValve were somewhat reduced with PBT, by −0.9 Gy (P = .04) and −1.7 Gy (P = .02), respectively.

Compared with photon RT, PBT delivered higher doses to the carotid arteries (average increase for all patients: +2.0 Gy; P < .001) but lower doses to the lungs (−2.2 Gy; P < .001), female breast (−0.9 Gy; P < .001), and esophagus (−1.2 Gy; P = .003). The reductions in lung and breast doses were greater for patients whose axilla was irradiated (lungs: −2.8 Gy; P < .001; breast: −1.8 Gy; P < .001; Table 2).
The background CVD AMR30 varied substantially between the 4 geographic regions considered. For the United States, the rate was 2.8%, which is almost double that of the Western European population (1.6%) and just over half that of the Eastern European population (4.5%). The Japanese population had the lowest CVD AMR30 (1.2%; Fig. 1).

Lastly, PBT halved the total normal tissue dose compared with photon RT (2.3 vs 4.7 Gy; $P < .001$; Table 2). Further details of the dosimetric comparison for additional cardiac substructures and OARs are provided in Supplemental Table E5.

### Treatment-related absolute 30-year mortality risks in different geographic regions

The dose–response relationships suggest that both chemotherapy and RT have multiplicative effects on background mortality rates, sometimes varying with age at the time of treatment (Supplemental Table E3). Therefore, estimates of the treatment-related increase in the CVD AMR30 also varied substantially between the different geographic regions and between male and female patients (Figs. 1 and 2; Table 3). Despite this, when the CVD AMR30 for PBT and photon RT were compared, either for all patients with HL or just for those whose CTV extended below the LMSCA, the reductions for PBT compared with photon RT were small (Table 3). However, for the approximately 30% of patients whose CTV overlapped longitudinally with the heart by ≥40%, the reductions were more substantial. For example, for U.S. background rates, the total AMR30 for CVD after treatment was reduced by 0.8%, from 7.0% with photon RT to 6.2% with PBT (Table 3). Additionally, the

| Organ at risk; (notation for dose) | Patient group | Photon RT (Gy); average (range) | PBT (GyE*); average (range) | Absolute difference (Gy); average (range) | $P$ value for absolute difference | $P$ value for difference between patient subgroups |
|-----------------------------------|---------------|--------------------------------|-----------------------------|------------------------------------------|-----------------------------------|-----------------------------------------------|
| Whole heart (mean)                | All           | 9.5 (0.6-26.1)                 | 8.7 (1.0-20.7)              | –0.7 (–12.5 to 5.8)                     | .06                                | –                                             |
|                                   | <40%          | 6.7 (0.6-13.5)                 | 7.1 (1.0-14.3)              | +0.4 (–6.5 to 5.8)                      | .29                                | <.001                                        |
| ≥40%                              |               | 16.5 (9.6-26.1)                | 13.3 (7.5-20.7)             | –3.2 (–12.5 to 3.3)                     | <.001                              | <.001                                        |
|                                   | Above LMSCA    | 3.0 (0.6-6.0)                  | 4.1 (1.0-7.2)               | +1.1 (0.4-2.6)                          | .15                                | .02                                           |
|                                   | Below LMSCA    | 10.9 (3.3-26.1)                | 9.9 (3.5-20.7)              | –1.0 (–12.5 to 5.8)                     | <.01                               | –                                             |
| Left Ventricle (mean)             | All           | 5.4 (0.2-23.9)                 | 3.1 (0.0-14.4)              | –2.2 (–18.0 to 3.9)                     | <.001                              | –                                             |
|                                   | <40%          | 3.0 (0.2-9.1)                  | 2.1 (0.0-10.0)              | –0.9 (–7.5 to 2.7)                      | .04                                | <.001                                        |
| ≥40%                              |               | 11.2 (2.9-23.9)                | 5.7 (0.1-14.4)              | –5.6 (–18.0 to 3.9)                     | <.001                              |                                              |
|                                   | Above LMSCA    | 0.9 (0.2-1.38)                 | 0.7 (0.1-2.4)               | –0.2 (–1.0 to 1.2)                      | .82                                | .013                                          |
|                                   | Below LMSCA    | 6.3 (0.7-23.9)                 | 3.6 (0.1-14.4)              | –2.7 (–18.0 to 3.9)                     | <.001                              |                                              |
| Heart valves (SumValve)           | All           | 14.1 (0.4-28.3)                | 11.4 (0.1-29.2)             | –2.7 (–19.5 to 8.4)                     | <.001                              | –                                             |
|                                   | <40%          | 11.2 (0.4-24.1)                | 9.5 (0.1-29.2)              | –1.7 (–19.5 to 8.4)                     | .02                                | <.01                                          |
| ≥40%                              |               | 21.0 (9.1-28.3)                | 15.9 (6.8-27.2)             | –5.1 (–17.3 to 6.8)                     | <.001                              |                                              |
|                                   | Above LMSCA    | 4.5 (0.4-12.7)                 | 6.3 (0.1-14.9)              | +1.7 (–1.9 to 8.4)                      | .20                                | <.01                                          |
|                                   | Below LMSCA    | 16.1 (3.0-28.3)                | 12.5 (1.0-29.2)             | –3.6 (–19.5 to 6.8)                     | <.001                              |                                              |
| Carotid arteries                  | All           | 25.1 (2.8-30.2)                | 27.1 (7.9-31.6)             | +2.0 (–1.6 to 8.7)                      | <.001                              | –                                             |
| Lungs                             | All           | 7.9 (3.7-14.6)                 | 5.7 (2.4-10.1)              | –2.2 (–7.1 to 0.41)                     | <.001                              | –                                             |
|                                   | No axilla      | 7.1 (3.7-14.1)                 | 5.2 (2.4-9.6)               | –1.9 (–4.5 to 0.41)                     | <.001                              | <.01                                          |
|                                   | Axilla         | 9.5 (6.5-14.6)                 | 6.6 (3.7-10.1)              | –2.8 (–7.1 to 0.16)                     | <.001                              |                                              |
| Breast                            | All           | 2.5 (0.4-8.7)                  | 1.6 (0.2-4.6)               | –0.9 (–5.6 to 1.1)                      | <.001                              | –                                             |
|                                   | No axilla      | 2.0 (0.4-6.5)                  | 1.5 (0.2-4.2)               | –0.5 (–2.3 to 0.6)                      | .03                                | <.001                                        |
|                                   | Axilla         | 3.7 (0.7-8.7)                  | 1.9 (0.5-4.6)               | –1.8 (–6.0 to 1.1)                      | <.001                              |                                              |
| Esophagus                         | All           | 16.4 (5.4-24.4)                | 15.2 (0.3-24.5)             | –1.2 (–9.7 to 8.2)                      | <.01                               | –                                             |
| Total normal tissue               | All           | 4.7 (1.6-8.6)                  | 2.3 (0.7-6.2)               | –2.4 (–6.4 to 0.5)                      | <.001                              | –                                             |

*Abbreviations: CTV = clinical target volume; LMSCA = left main stem coronary artery; PBT = proton beam therapy; RT = radiation therapy. Dose metrics for additional organs at risk and target volumes are shown in Table E5. 
* GyE is Gy equivalent of relative biologic effectiveness of 1.1 with PBT 
* %CTV to heart longitudinal overlap was < or ≥40% 
* CTV was above LMSCA only or extended below LMSCA 
* SumValve = (0.553 × AVMean) + (0.368 × MVMean) + (0.079 × TVMean). This is a weighted average of the mean doses to the aortic valve (AVMean), mitral valve (MVMean), and tricuspid valve (TVMean) based on data by Cutter et al. 
* Average mean dose to left and right common carotid arteries 
* Female patients only 
* Mean dose to whole body minus RT planning target volume

The dose–response relationships suggest that both chemotherapy and RT have multiplicative effects on background mortality rates, sometimes varying with age at the time of treatment (Supplemental Table E3). Therefore, estimates of the treatment-related increase in the CVD AMR30 also varied substantially between the different geographic regions and between male and female patients (Figs. 1 and 2; Table 3). Despite this, when the CVD AMR30 for PBT and photon RT were compared, either for all patients with HL or just for those whose CTV extended below the LMSCA, the reductions for PBT compared with photon RT were small (Table 3). However, for the approximately 30% of patients whose CTV overlapped longitudinally with the heart by ≥40%, the reductions were more substantial. For example, for U.S. background rates, the total AMR30 for CVD after treatment was reduced by 0.8%, from 7.0% with photon RT to 6.2% with PBT (Table 3). Additionally, the

The dose–response relationships suggest that both chemotherapy and RT have multiplicative effects on background mortality rates, sometimes varying with age at the time of treatment (Supplemental Table E3). Therefore, estimates of the treatment-related increase in the CVD AMR30 also varied substantially between the different geographic regions and between male and female patients (Figs. 1 and 2; Table 3). Despite this, when the CVD AMR30 for PBT and photon RT were compared, either for all patients with HL or just for those whose CTV extended below the LMSCA, the reductions for PBT compared with photon RT were small (Table 3). However, for the approximately 30% of patients whose CTV overlapped longitudinally with the heart by ≥40%, the reductions were more substantial. For example, for U.S. background rates, the total AMR30 for CVD after treatment was reduced by 0.8%, from 7.0% with photon RT to 6.2% with PBT (Table 3). Additionally, the
background CVD AMR\textsubscript{30} for men was double that for women; thus, the predicted treatment-related AMR\textsubscript{30} was also double. For example, for U.S. background rates, for patients whose CTV overlapped longitudinally with the heart by $\geq 40\%$, the total AMR\textsubscript{30} was 9.7\% for photon RT and 8.6\% for PBT for men versus 5.0\% for photon RT and 4.4\% for PBT for women, showing a benefit from PBT in both sexes for this subgroup (Fig. 2). However, for patients with $<40\%$ overlap, the AMR\textsubscript{30} for photon RT and PBT was similar (men: 6.95\% and 7.00\%; women: 3.80\% and 3.85\%).

The chemotherapy-related increase in the CVD AMR\textsubscript{30} was substantial and, in some cases, exceeded the radiation-related AMR (Fig. 1).

The background AMR\textsubscript{30} for SC varied less across the 4 regions than for CVD; thus, treatment-related increases in AMR\textsubscript{30} also differed less across regions. The total AMR\textsubscript{30} for lung cancer was 2 to 3 times higher than the AMR\textsubscript{30} for breast cancer and up to 10 times higher than that for esophageal cancer (Fig. 1). The radiation-related increase in lung cancer AMR\textsubscript{30} was smaller for PBT than for photon-RT and, considering all patients with HL in conjunction with U. S. background rates, AMR\textsubscript{30} was reduced by 0.4\% with PBT from 2.4\% to 2.0\% (Fig. 1). When patients with treated axillae were considered separately, the absolute difference in lung cancer AMR\textsubscript{30} between PBT and photon RT was slightly larger when the axilla was irradiated than when not (0.6\% vs 0.4\%; Table 3), and the difference was similar for men and women (Fig. 2). The AMR\textsubscript{30} for both female breast and esophageal cancers was lower than for either CVD or lung cancer, and the differences between PBT and photon RT were negligible (Fig. 1; Table 3).

Smoking

Smoking had a strong influence on the predicted AMR\textsubscript{30} for both CVD and lung cancer and on the differences between PBT and photon RT. For the U.S. background rates, the AMR\textsubscript{30} for CVD for a 30-year-old male or female typical current smoker was more than double that for a never-smoker of the same age (male: 3.7\% vs 1.7\%; female: 1.8\% vs 0.8\%), and the background AMR\textsubscript{30} for lung cancer was 14 times higher in current smokers than in never-smokers (male: 4.0\% vs 0.3\%; female: 4.2\% vs 0.3\%; Fig. 3). In fact, a
| Disease       | Patient group* | United States        | Average cumulative absolute mortality risk (%) (range) | Western Europe† | Eastern Europe† | Japan          |
|--------------|----------------|----------------------|--------------------------------------------------------|----------------|----------------|----------------|
|              |                | CT + photons         |                         | CT + PBT       | CT + photons   | CT + photons   | CT + PBT       |
| CVD          | All patients   | 5.6 (0.9-27.2)       | 3.2 (0.3-27.8)          | 9.7 (1.0-48.0) | 2.7 (0.3-22.0) | 2.5 (0.3-21.9) |
|              | <40%‡          | 5.3 5.3              | 3.1                     | 9.2 9.2        | 2.5           | 2.5           |
|              | ≥40%‡          | 7.0 6.2              | 3.8 3.5                 | 11.1 10.3      | 3.0           | 2.8           |
|              | Above LMSCA§   | 4.7 4.9              | 2.8 2.9                 | 8.5 8.7        | 2.3           | 2.4           |
|              | Below LMSCA§   | 5.9 5.7              | 3.4 3.3                 | 9.9 9.7        | 2.7           | 2.6           |
| Lung cancer  | All patients   | 2.4 (0.2-11.6)       | 2.4 (0.1-13.0)          | 2.7 (0.1-13.3) | 1.6 (0.1-13.0) | 1.3 (0.1-12.2) |
|              | No axilla      | 2.3 1.9              | 2.3 1.9                 | 2.4 2.0        | 1.4           | 1.2           |
|              | Axilla         | 2.7 2.1              | 2.7 2.2                 | 3.0 2.3        | 1.8           | 1.4           |
| Breast cancer| All women      | 0.7 (0.2-1.4)        | 0.7 (0.2-1.5)           | 0.8 (0.3-1.6)  | 0.6 (0.2-1.0) | 0.5 (0.2-1.0) |
|              | No axilla      | 0.7 0.7              | 0.7 0.7                 | 0.8 0.8        | 0.6           | 0.5           |
|              | Axilla         | 0.7 0.7              | 0.8 0.7                 | 0.9 0.8        | 0.6           | 0.5           |
| Esophageal cancer | All patients | 0.2 (0.0-1.4)       | 0.3 (0.0-1.5)          | 0.2 (0.0-1.3)  | 0.3 (0.0-2.1) | 0.3 (0.0-2.6) |

Abbreviations: CT = chemotherapy; CTV = clinical target volume; CVD = cardiovascular disease; LMSCA = left main stem coronary artery; PBT = proton beam therapy; RT = radiation therapy

* Subgroups are directly standardized for age and sex as described in Appendix B.
† The countries comprising Western and Eastern Europe are listed in Table E1.
‡ %CTV to heart longitudinal overlap was < or ≥40%
§ CTV was above LMSCA only or extended below LMSCA
∥ Female patients only (n = 50)
Fig. 2. Predicted 30-year absolute mortality risk (AMR$_{30}$) for all cardiovascular disease and lung cancer as a second primary cancer for male and female patients. Average AMR$_{30}$ for cardiovascular disease is presented for patients with $\geq$40% or $<40\%$ clinical target volume to the heart longitudinal overlap and for lung cancer for patients with and without axillary disease. The background AMR$_{30}$ was calculated using standardized U.S. mortality rates. The chemotherapy-related AMR$_{30}$ was predicted using excess rate ratios by Van Nimwegen et al. The radiation therapy-related AMR$_{30}$ was predicted using the excess relative risks from the studies in Supplemental Table E3, combined with the average radiation dose for each subgroup as shown in Table 2 assigned to every patient. Further details are provided in Appendix B.
Fig. 3. Predicted 30-year absolute mortality risks (AMR$_{30}$) for all cardiovascular disease and lung cancer as a second primary cancer after photon radiation therapy and proton beam therapy for male and female 30-year-old current smokers and male and female 30-year-old never smokers. The background mortality was calculated using U.S. mortality rates. The chemotherapy-related risk was calculated using excess rate ratios by Van Nimwegen et al.$^1$ The radiation-related AMR for cardiovascular disease was calculated assuming the average mean whole heart, left ventricle, and valve doses in patients with ≥40% clinical target volume to the heart overlap. For lung cancer, the average mean lung dose received by patients with axillary disease was used. These doses are shown in Table 2, and further details are provided in Appendices B and C.
30-year-old current smoker who did not receive any treatment for HL had a predicted CVD AMR$_{30}$ almost as big as that for a never-smoker of the same age and sex who received anthracycline chemotherapy followed by RT with high cardiac doses, such as those received by patients with ≥40% CTV-to-heart overlap.

An even stronger effect was observed for lung cancer where just the background lung cancer AMR$_{30}$ for a current smoker was almost 10 larger than that for a never-smoker of the same age and sex who received anthracycline and high cardiac dose RT. Accordingly, compared with photon RT, PBT provided a larger absolute benefit in AMR$_{30}$ reduction for current smokers than for never-smokers.

**Discussion**

This is the first study to identify subgroups of patients who are likely to benefit from PBT versus optimal photon RT, not only dosimetrically but also by using the more clinically meaningful endpoints of predicted AMR$_{30}$ for CVD and SC. Clinical data from a large group of patients with HL and mediastinal disease already treated with advanced PBT were used to evaluate the recent ILROG guidelines for patient selection, as well as explore possible new selection criteria. In addition, the effect of other risk factors, such as background population risk from 27 countries across 4 geographic regions, chemotherapy-related risk, and smoking, were considered for the first time.

One of the most important findings of this study is that smoking increases treatment-related AMR$_{30}$ from CVD and lung cancer to a much larger extent than the reduction seen in these measures when PBT is used instead of photon RT. For example, just the background lung cancer AMR$_{30}$ for a current smoker was almost 10 times larger than that for a never-smoker of the same age and sex who received anthracycline and a high cardiac RT dose. Therefore, although PBT provided a benefit compared with photon RT in AMR$_{30}$ reduction for current smokers, smoking cessation would reduce these risks much more. Additionally, the differences in background 30-year risk between regions at times dwarfed the differences between RT modalities within the same region. For example, on average, the background AMR$_{30}$ for CVD for the U.S. population was almost as high as the background AMR$_{30}$ plus the additional risk from RT and chemotherapy combined for the Western European population.

These findings demonstrate that considering dosimetric factors alone is inadequate when determining PBT referral criteria, and that the magnitude of other background risk factors for CVD and cancer (eg, smoking) can be more relevant. In addition, these findings highlight the importance of active intervention regarding modifiable risk factors, in particular smoking cessation advice in young patients with HL, to reduce future CVD and lung cancer mortality risk.

Frequent screening of higher-risk survivors (eg, smokers) after treatment could also reduce lung cancer mortality risk. The study shows that, for a cohort of patients selected clinically and treated with PBT, the predicted benefit of PBT is not universal and limited to certain categories of patients. This confirms the need for reliable, pragmatic selection criteria to obtain a meaningful benefit from this scarce and expensive technology. When patients were assessed as a whole group, PBT significantly reduced doses to most OARs compared with optimal photon RT, but the reductions in the overall average AMR$_{30}$ were small. This is consistent with the findings by Rechner et al., who found small differences for all patients considered together when comparing estimated life-years lost between PBT and photon RT in DIBH. If the available alternative to PBT is a less optimal photon RT method, PBT may well provide substantial benefits for a larger proportion of patients.

For cardiac doses and CVD AMR$_{30}$, we investigated the ILROG recommendation suggesting that patients with mediastinal disease extending below the origin of the LMSCA may benefit more from PBT. In our study, 82% of patients fell within this category and, on average, benefitted dosimetrically from PBT compared with those with disease only above the LMSCA (Table 2). The patients also benefitted somewhat in terms of CVD AMR$_{30}$ (Table 3); thus, validating the ILROG recommendation. However, larger reductions in dose and CVD AMR$_{30}$ were observed for the approximately 30% of patients whose CTV overlapped longitudinally with the heart by ≥40%, but there was no reduction in CVD AMR$_{30}$ for those with a <40% overlap (Tables 2 and 3). Using U.S. background rates, the reduction in CVD AMR$_{30}$ from PBT was 0.2% based on the ILROG-LMSCA guidelines and 0.8% based on the overlap between the RT target volume (CTV) and the heart. This more selective threshold identifies patients who will benefit more from PBT, and could help with case selection when access to PBT is limited.

The second group identified by ILROG was patients requiring RT for axillary disease, particularly young women, owing to reduced exposure of the lung and breasts from PBT. In our study, PBT reduced the lung dose and lung cancer AMR$_{30}$ for all patients, and those whose field included the axilla had greater benefits (Tables 2 and 3). This shows a clear advantage of using PBT to reduce lung dose, even compared with BVMAT, despite the latter being effective at sparing lung tissue. Both PBT and photon RT spared the breasts, and the AMR$_{30}$ was low for both techniques, with little additional predicted benefit with PBT. However, if optimal breast-sparing photon RT is not available, referring young women (age ≤24 years) for PBT may be appropriate, because they have a higher relative risk of breast cancer per Gy of breast dose received compared with older women (Supplemental Table E3). Of note, the AMR$_{30}$ for lung cancer was 2 to 3 times higher than that for breast cancer and up to 10 times higher than that for esophageal cancer (Fig. 1). Contrary to popular belief that PBT should be widely used to reduce breast cancer risk, our study shows...
that the main mortality benefit of PBT was to reduce lung cancer AMR$_{30}$. However, of note, our data relate to mortality risk, not incidence of breast cancer, and the conclusions may be different if incidence was the outcome rather than AMR$_{30}$.

Our study also shows that PBT reduced the total normal tissue dose, spinal cord dose, and volumetric lung doses, such as $V_5$ and $V_{20}$ (ie, percentage volume of lung receiving at least 5 Gy and 20 Gy, respectively; Table 2; Supplemental Table E5). This is particularly beneficial for patients with relapsed disease who have already received RT because the risk of acute cord and bone marrow toxicities may lower, as well as the risk of radiation pneumonitis.

The mean OAR doses for the PBT plans in our patients were comparable with those of previous studies, but our photon RT doses were lower than in other studies. For example, the average MHD, MLD, and MBD for photon RT in our study was 9.5 Gy, 7.9 Gy, and 2.5 Gy, respectively, but a recent review of 16 studies in patients with mediastinal HL reported an average MHD, MLD, and MBD of 11.4 Gy, 9.4 Gy, and 4.4 Gy, respectively. As a result, the differences between PBT and photon RT are narrower than the differences reported in the latest critical review by the Particle Therapy Cooperative Group lymphoma subcommittee. At least in part, this is because we maximized the use of partial-arc techniques; thus, avoiding the breasts and lateral parts of the lungs.

An additional explanation could be the use of smaller CTV–PTV margins for photon RT, resulting in smaller target volumes for the photon RT plans compared with PBT. These margins reflect current clinical practice within our photon and proton centers, and may be smaller than those at other centers. The reduction in the magnitude of the benefit from PBT in our study highlights the importance of continually comparing technologies as they develop and improve.

**Strengths**

This study is the largest study to date comparing patients with HL ($n = 80$) treated with optimal PBT technology using pencil beam scanning delivered in DIBH to optimal photon RT, and is the first to compare the AMR$_{30}$ for CVD and SC. Therefore, the study provides an accurate comparison between the best available form of the 2 technologies. We use a prediction method, based on contemporary age- and sex-specific background mortality rates from 27 countries, combined with treatment-related risks from epidemiologic studies of long-term HL survivors. This is the first time that the most clinically important predicted mortality risks for survivors have been combined in a model to compare PBT and photon RT.

Additionally, we predict the risk of CVD based on doses to individual cardiac substructures and arteries. This is more informative than using MHD, because there can be substantial differences between doses received by different structures due to the high conformity provided by modern photon and proton techniques. Estimating chemotherapy-related AMR$_{30}$ for CVD alongside radiation-related risks provides a useful perspective on the relationship between the excess risks from each treatment. This is also more clinically meaningful because all patients who receive RT will first have had chemotherapy. Lastly, illustrating the large detrimental effect of smoking provides novel data for clinicians to demonstrate to their patients the importance of smoking cessation during and after treatment for HL.

**Limitations**

A first limitation is that the study does not provide estimates of the absolute incidence of CVD or SC, which would be higher than mortality (AMR$_{30}$). This is particularly relevant to CVD and breast cancer for which incidence is many times higher than mortality. Unfortunately, country-specific incidence rates by sex and age are not currently available for individual CVD for the 27 countries used in this study; thus, calculating excess incidence rates was not possible.

Second, despite recent evidence for chemotherapy-related mortality risk of second breast cancer in patients with HL, there is no published dose–response relationship; thus, we could not take account of this additional risk in our model. Third, the late effects from HL treatments typically do not manifest for at least a decade after completion of therapy, and continue to develop beyond 30 years from treatment. This latency means that directly determining the risk of late effects from patients treated recently with modern RT is not yet possible. Instead, risk predictions based on dose–response relationships derived by the best currently available follow-up studies of patients with HL treated in the past combined with individual radiation doses received by patients treated with modern RT can provide useful approximate results, and determine the potential risk reductions achievable with modern treatment approaches.

Our results are based on such predictions, and there are uncertainties associated with these models, some of which can be quantified. Confidence intervals for the coefficients of the dose–response relationships are available (Supplemental Table E3), and the impact of dose–reconstruction uncertainties on them has previously been evaluated and found to be small. Additionally, as data are not available for traditional CVD risk factors, other than smoking, we cannot provide separate risks for patients with risk factors such as diabetes and elevated cholesterol levels. If such data became available, our models could be updated to demonstrate the effect of these additional risk factors. Lastly, all dose–response relationships used to predict AMR$_{30}$ from photon RT and PBT were derived from epidemiologic studies on patients with HL treated with photon RT only. Therefore, potential proton-specific effects (eg, those caused by uncertainties in the relative biologic effectiveness of protons) could not be taken into account.
Conclusions

Patients with supradiaphragmatic lymphoma who benefit the most from PBT compared with photon RT can be identified using simple and reliable criteria. Patients with low mediastinal disease (>40% CTV-to-heart longitudinal overlap) or axillary disease have a lower mortality risk from PBT, even compared with optimized photon RT, and prioritizing these individuals may be appropriate when selecting patients for PBT. Others might still receive a small dosimetric benefit with PBT, but our results suggest that this does not translate into a substantial mortality benefit.

This study also highlights the fact that, when deciding whether to refer a patient for photon RT or PBT, just considering dose comparisons is not sufficient. Background mortality risks vary considerably with age, sex, and between different geographic regions, and the effects of smoking and chemotherapy are substantial. All these factors will affect the absolute magnitude of the radiation-related risk for an individual patient. Smoking cessation should be strongly encouraged in smokers who require thoracic RT.

References

1. Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015;107:dy008.
2. van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol 2015;34:235–243.
3. Van Nimwegen FA, Ntetas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: Effects of cardiac exposure to radiation and anthracyclines. Blood 2017;129:2257–2265.
4. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002;94:182–192.
5. Morton LM, Gilbert ES, Stovall M, et al. Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica 2014;99:e193–e196.
6. Maraldo MV, Giusti F, Vogelius IR, et al. Cardiovascular disease after treatment for Hodgkin’s lymphoma: An analysis of nine collaborative EORTC-LYSA trials. Lancet Haematol 2015;2:e492–e502.
7. Aleman BMP, Van Den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–1886.
8. Specht L, Yahalom J, Ilidge T, et al. Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Radiation Oncology Research Group (ILROG). Int J Radiat Oncol Biol Phys 2014;89:854–862.
9. Voong KR, McSpadden K, Pinnix CC, et al. Dosimetric advantages of a “butterfly” technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin’s lymphoma. Radiat Oncol 2014;9:94.
10. Filippi AR, Ragona R, Piva C, et al. Optimized volumetric modulated arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: A comparison of second cancers and heart disease risk. Int J Radiat Oncol Biol Phys 2015;92:161–168.
11. Starke A, Bowden J, Lynn R, et al. Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma. Radiother Oncol 2018;129:449–455.
12. Schaapveld M, Aleman BMP, van Eggemond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med 2015;373:2499–2511.
13. Doros GM, Curtis RE, Dalal NH, Linet MS, Morton LM. Cause-specific mortality following initial chemotherapy in a population-based cohort of patients with classical Hodgkin lymphoma, 2000–2016. J Clin Oncol 2020;38:4149–4162.
14. Lagerlöf I, Holte H, Glimelius I, et al. No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. Br J Haematol 2020;188:685–691.
15. Conway JL, Connors JM, Tyldeyse S, et al. Secondary breast cancer risk by radiation volume in women with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2017;97:35–41.
16. Hoppe BS, Flamouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2012;84:449–455.
17. Ntetas G, Dedeckova K, Andrich M, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most? Pract Radiat Oncol 2019;9:179–187.
18. Moreno AG, Gunther JR, Milgrom S, et al. Effect of deep inspiration breath hold on normal tissue sparing with intensity modulated radiation therapy versus proton therapy for mediastinal lymphoma. Adv Radiat Oncol 2020;5:1255–1266.
19. Dabaja BS, Hoppe BS, Plantaras JP, et al. Proton therapy for adults with mediastinal lymphomas: The International Lymphoma Radiation Oncology Group guidelines. Blood 2018;132:1635–1646.
20. Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011;79:10–18.
21. Duane F, Azznar MC, Bartlett F, et al. A cardiac contouring atlas for radiotherapy. Radiother Oncol 2017;122:416–422.
22. Swaensk P, Hafez O, Attallah H, Hall K, Brady J, Mikhail G. Is 5 mm CTV-PVT margin adequate for mediastinal lymphoma treated in DIBH? Int J Radiat Oncol Biol Phys 2020;98:e573.
23. Levis M, Filippi AR, Fiandra C, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin’s lymphoma patients. Radiother Oncol 2019;138:52–58.
24. World Health Organization. Mortality database. Available at: https://www.who.int/healthinfo/mortality_data/en/. Accessed January 1, 2017.
25. De Bruin ML, Dorresteijn LD, Van’t Veer MB, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009;101:928–937.
26. Peto R, Darby S, Deo H, Silcock P, Whiteley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: Combination of national statistics with two case-control studies. Br Med J 2000;321:323–329.
27. Field JK, Valkan D, Davies MP, et al. Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur 2021;10:100179.
28. Rechner LA, Maraldo MV, Vogelius IR, et al. Life years lost attributable to late effects after radiotherapy for early stage Hodgkin lymphoma: The impact of proton therapy and/or deep inspiration breath hold. Radiother Oncol 2017;125:41–47.
29. Pinnix CC, Smith GL, Milgrom S, et al. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2015;92:175–182.
30. Ricardi U, Maraldo MV, Levis M, Parikh RR. Proton therapy for lymphomas: Current state of the art. Onco Targets Ther 2019;12:8033–8046.
31. Tseng YD, Cutter DJ, Plantaras JP, et al. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee. Int J Radiat Oncol Biol Phys 2017;99:825–842.
32. Filippi AR, Levis M, Parikh R, Hoppe B. Optimal therapy for early-stage Hodgkin’s lymphoma: Risk adapting, response adapting, and role of radiotherapy. Curr Oncol Rep 2017;19:34.
33. Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiation therapy era. Pract Radiat Oncol 2020;10:e147–e154.
34. Neppelenbroek SIM, Geurts YM, Aleman BMP, et al. Anthracycline exposure and breast cancer risk in female Hodgkin lymphoma survivors. *J Clin Oncol* 2021;39:12074.

35. Veiga LH, Curtis RE, Morton LM, et al. Association of breast cancer risk after childhood cancer with radiation dose to the breast and anthracycline use: A report from the Childhood Cancer Survivor Study. *JAMA Pediatr* 2019;173:1171–1179.

36. van Nimwegen FA, Schaapveld M, Janus CPM, et al. Cardiovascular disease after Hodgkin lymphoma treatment 40-year disease risk. *JAMA Intern Med* 2015;175:1007–1017.

37. Cutter DJ, Ramroth J, Diez P, et al. Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography-directed therapy for early-stage Hodgkin lymphoma. *J Clin Oncol* 2021;39:3591–3601.

38. Ntentas G, Darby SC, Aznar MC, et al. Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction. *Radiother Oncol* 2020;153:155–162.

39. Paganetti H. Relating proton treatments to photon treatments via the relative biological effectiveness - Should we revise current clinical practice? *Int J Radiat Oncol Biol Phys* 2015;91:892–894.